Pfizer surprises Street with Vyndaqel sales, uptake

Uptake of Pfizer's Vyndaqel tafamidis in 3Q19 surpassed a consensus estimate following its approval in May, adding to expectations for a drug the pharma has already touted as a potential blockbuster to treat transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

Pfizer Inc. (NYSE:PFE) said Vyndaqel sales jumped to $156 million worldwide from $63 million in 2Q19; U.S. sales rose to $79 million from $8 million sequentially. Analysts were expecting U.S. sales of $21 million for the quarter, according to Evercore ISI analyst Umer Raffat...